AQST vs. CHMA, XERS, SCPH, OPTN, CMRX, IRWD, COLL, SAVA, INVA, and CVAC
Should you be buying Aquestive Therapeutics stock or one of its competitors? The main competitors of Aquestive Therapeutics include Chiasma (CHMA), Xeris Biopharma (XERS), scPharmaceuticals (SCPH), OptiNose (OPTN), Chimerix (CMRX), Ironwood Pharmaceuticals (IRWD), Collegium Pharmaceutical (COLL), Cassava Sciences (SAVA), Innoviva (INVA), and CureVac (CVAC). These companies are all part of the "medical" sector.
Aquestive Therapeutics (NASDAQ:AQST) and Chiasma (NASDAQ:CHMA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, community ranking, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.
Aquestive Therapeutics presently has a consensus price target of $8.00, indicating a potential upside of 188.81%. Given Aquestive Therapeutics' higher probable upside, equities research analysts plainly believe Aquestive Therapeutics is more favorable than Chiasma.
Chiasma received 54 more outperform votes than Aquestive Therapeutics when rated by MarketBeat users. However, 66.78% of users gave Aquestive Therapeutics an outperform vote while only 50.80% of users gave Chiasma an outperform vote.
Chiasma has a net margin of 0.00% compared to Aquestive Therapeutics' net margin of -55.85%. Aquestive Therapeutics' return on equity of 0.00% beat Chiasma's return on equity.
In the previous week, Aquestive Therapeutics had 8 more articles in the media than Chiasma. MarketBeat recorded 8 mentions for Aquestive Therapeutics and 0 mentions for Chiasma. Aquestive Therapeutics' average media sentiment score of 0.54 beat Chiasma's score of 0.46 indicating that Aquestive Therapeutics is being referred to more favorably in the media.
Aquestive Therapeutics has a beta of 2.81, suggesting that its stock price is 181% more volatile than the S&P 500. Comparatively, Chiasma has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.
Aquestive Therapeutics has higher revenue and earnings than Chiasma. Aquestive Therapeutics is trading at a lower price-to-earnings ratio than Chiasma, indicating that it is currently the more affordable of the two stocks.
32.5% of Aquestive Therapeutics shares are owned by institutional investors. Comparatively, 61.7% of Chiasma shares are owned by institutional investors. 7.9% of Aquestive Therapeutics shares are owned by company insiders. Comparatively, 8.3% of Chiasma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Aquestive Therapeutics beats Chiasma on 12 of the 18 factors compared between the two stocks.
Get Aquestive Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for AQST and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AQST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aquestive Therapeutics Competitors List
Related Companies and Tools
